search
Back to results

Validation of Endoscopic Bimodal Imager for the Bladder Cancer Detection (CyPaM2)

Primary Purpose

Bladder Cancer

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Strorz (commercial)
CyPaM2 (experimental)
Sponsored by
Institut de Cancérologie de Lorraine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Bladder Cancer focused on measuring Bladder cancer, Hexvix, Bimodal Endoscopic Imager, Cystoscopy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age >18 years
  • Patient with suspicion of a bladder cancer or a suspected recurrence of a bladder cancer
  • Cytological and bacteriological examination of urine culture negative
  • Patient must be affiliated to a social security system
  • Ability to provide written informed consent patient's legal capacity to consent to study participation and to understand and comply with the requirements of the study

Exclusion Criteria:

  • Age < 18 years
  • Bladder infection in progress and untreated
  • Hemorrhage
  • Urethral stenosis
  • Contraindication for a cystoscopy examination
  • Contraindication to administration of Hexvix (porphyria, hypersensitivity to hexylaminolévulinate or excipient of Hexvix (disodium phosphate dihydrate, potassium dihydrogen phosphate)
  • Pregnant or breast feeding females
  • Patients deprived of liberty or under supervision

Sites / Locations

  • Institut de Cancerologie de Lorraine

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Experimental

Arm Description

Patients with a suspicion of a bladder cancer or suspected recurrence of bladder cancer will have a cystoscopy under their care. Patients will be randomized to know the order of carrying out cystoscopy with one or the other medical devices. 24 hours and 48 hours after the exam, a nurse will contact the patient to detect potential adverse effects

Outcomes

Primary Outcome Measures

Ergonomic comparaison of the two devices
Ergonomic of the two devices will be evaluated and compared by using the scale NASA TLX (Hart SG, et al., 1998).

Secondary Outcome Measures

Comparison of performing time
Performing time of medical examination with both devices will be evaluated and compared
Quality assessment of image
Image quality : sharpness and colorimetry will be assessed by the physician using a self-questionnaire.
Quality assessment of device evaluation
Device quality : sensitivity and accuracy will be assessed by the urologist using a self-questionnaire
Evaluation of recording capacity of the video sequences to perform real-time image mosaics
Recording capacity of the video sequences to perform real-time image mosaics will be assessed by the physician using a self-questionnaire

Full Information

First Posted
June 6, 2016
Last Updated
March 4, 2021
Sponsor
Institut de Cancérologie de Lorraine
search

1. Study Identification

Unique Protocol Identification Number
NCT02800473
Brief Title
Validation of Endoscopic Bimodal Imager for the Bladder Cancer Detection
Acronym
CyPaM2
Official Title
Evaluation of an Innovative Medical Device Made of a Bimodal Endoscopic Imager and of a Software for Panoramic Images Building of the Bladder Inner Wall (French National Research Agency, CyPaM2 Project, ANR-11-TECS-001) (CyPaM2)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
July 4, 2016 (Actual)
Primary Completion Date
October 4, 2017 (Actual)
Study Completion Date
October 6, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut de Cancérologie de Lorraine

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the therapeutic value of: (i) simultaneous endoscopic visualization of the inner bladder using white light and blue light excitations and (ii) high resolution panoramic images of the bladder inner wall. All participants will undergo fluorescence cystoscopy: the first half using first a reference medical device for fluorescence cystoscopy already on the market then using the innovative device specifically developped for the CyPaM2 project. The other half will undergo fluorescence cystoscopy using first the innovative then the reference medical device.
Detailed Description
An innovative medical device was developped by the CyPaM2 project's partners.This device is made of a hardware and of a software part: (i) an imager (light source and sensors) for simultaneous and colocalized visualisation of the bladder using white light and blue light for fluorescence excitation and (ii) a mosaicing software for automatic building of high-resolution panoramic images of the bladder inner wall. The medical device's qualitative (human engineering, images qualitty) and quantitative (medical examination and panoramic images building durations) specifications will be evaluated during the clinical trial in comparison with a reference medical device already on the market. The main goals are to achieve (i) better sensitivity of bladder cancers' cystocopic diagnosis and shorter medical examination durations thanks to the simultaneous visualization of the bladder inner wall with white and blue lights and (ii) better patients' follow up thanks to the high resolved panoramic images.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bladder Cancer
Keywords
Bladder cancer, Hexvix, Bimodal Endoscopic Imager, Cystoscopy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental
Arm Type
Other
Arm Description
Patients with a suspicion of a bladder cancer or suspected recurrence of bladder cancer will have a cystoscopy under their care. Patients will be randomized to know the order of carrying out cystoscopy with one or the other medical devices. 24 hours and 48 hours after the exam, a nurse will contact the patient to detect potential adverse effects
Intervention Type
Device
Intervention Name(s)
Strorz (commercial)
Intervention Type
Device
Intervention Name(s)
CyPaM2 (experimental)
Primary Outcome Measure Information:
Title
Ergonomic comparaison of the two devices
Description
Ergonomic of the two devices will be evaluated and compared by using the scale NASA TLX (Hart SG, et al., 1998).
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Comparison of performing time
Description
Performing time of medical examination with both devices will be evaluated and compared
Time Frame
1 day
Title
Quality assessment of image
Description
Image quality : sharpness and colorimetry will be assessed by the physician using a self-questionnaire.
Time Frame
1 day
Title
Quality assessment of device evaluation
Description
Device quality : sensitivity and accuracy will be assessed by the urologist using a self-questionnaire
Time Frame
1 day
Title
Evaluation of recording capacity of the video sequences to perform real-time image mosaics
Description
Recording capacity of the video sequences to perform real-time image mosaics will be assessed by the physician using a self-questionnaire
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age >18 years Patient with suspicion of a bladder cancer or a suspected recurrence of a bladder cancer Cytological and bacteriological examination of urine culture negative Patient must be affiliated to a social security system Ability to provide written informed consent patient's legal capacity to consent to study participation and to understand and comply with the requirements of the study Exclusion Criteria: Age < 18 years Bladder infection in progress and untreated Hemorrhage Urethral stenosis Contraindication for a cystoscopy examination Contraindication to administration of Hexvix (porphyria, hypersensitivity to hexylaminolévulinate or excipient of Hexvix (disodium phosphate dihydrate, potassium dihydrogen phosphate) Pregnant or breast feeding females Patients deprived of liberty or under supervision
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ESCHWEGE PASCAL, Pr
Organizational Affiliation
Institut de Cancérologie de Lorraine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institut de Cancerologie de Lorraine
City
Vandoeuvre-les-Nancy
ZIP/Postal Code
54519
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31873695
Citation
Amouroux M, Salleron J, Huin-Schohn C, Ali S, Berthaud S, Rizo P, Schneider S, Vever-Bizet C, Bourg-Heckly G, Guillemin F, Le Coupanec P, Galbrun E, Daouk J, Daul C, Blondel W, Eschwege P. Clinical evaluation of a device providing simultaneous white-light and fluorescence video streams as well as panoramic imaging during fluorescence assisted-transurethral resection of bladder cancer. J Opt Soc Am A Opt Image Sci Vis. 2019 Nov 1;36(11):C62-C68. doi: 10.1364/JOSAA.36.000C62.
Results Reference
background

Learn more about this trial

Validation of Endoscopic Bimodal Imager for the Bladder Cancer Detection

We'll reach out to this number within 24 hrs